Spotlight on the EpicentRx Family


American Society of Clinical Oncology (ASCO)

May 31-June 4, 2024 – Chicago, Illinois
Oral Presentation: Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.
Learn more

Oncolytic Virotherapy Summit 2023

December 2023; Boston, MA
Oral Presentation: Evaluating the Advantages & Hurdles of Intratumoral Delivery of Oncolytic Viruses

Inflammasome Therapeutics Summit

November 2023; Boston, Massachusetts
Oral Presentation: The Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases

Neuroscience 2023

November 2023; Washington D.C.
Oral Presentation: The CNS-permeable NLRP3 inhibitor RRx-001 is neuroprotective in experimental models of Parkinson’s disease

American Society of Clinical Oncology (ASCO) Annual Meeting 2023

June 2023; Chicago, Illinois
Poster: RRX-001 Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001 TGF-ß Trap (NCT04673942)

Poster: RRX-001, KEVLARx: A phase 2b, multi-institutional, randomized, blinded, controlled trial to assess the safety and efficacy of two schedules of RRx-001 vs. SOC in attenuating severe oral mucositis (SOM) in patients receiving concomitant chemoradiation (CRT) for the treatment of locally advanced squamous cell carcinomas (SCC) of the oral cavity (OC) or oropharynx (OPC).

SITC 2023 Spring Scientific

March 2023, Denver Colorado
Poster: TRIAL-IN-PROGRESS BETA-PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors (NCT04673942)
Poster: Low dose but not high dose RRx-001 repolarizes tumor associated macrophages from an M2 to M1 phenotype in colorectal cancer

3rd TGF-B for Immuno-Oncology Drug Development Summit 2023

January 2023, San Francisco, California
Oral Presentation: Exploring the Clinical Stage TGF-β Fusion Protein Expressing Oncolytic Virus, AdAPT-001

  • Highlighting the safety and tolerability of TGF-β targeting OV, AdAPT-001
  • Using correlative studies for measuring expression in the clinic
  • Discussing neutralizing TGF-β for improving checkpoint inhibitors

San Antonio Breast Cancer Summit (SABCS) 2022

December 2022, San Antonio, Texas
Poster: Treatment of 4T1 Breast Cancer with Liposome-Encapsulated AdAPT-001, a TGF-beta Trap Encoded Oncolytic Adenovirus Currently in a Phase 1/2 Anticancer Trial

4th Inflammasome Therapeutics Summit 2022

November 2022, Boston, Massachusetts
Oral Presentation: RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases

  • Evaluate strategy and execution of drug design and translational development
  • Understanding relevant pathology of disease and most up to date learnings on the inflammasome mechanisms, drug design, and patient population
  • Exploring the latest data, potential biomarkers, challenges, and future directions

Alzheimer’s Association International Conference (AAIC) 2022

July 2022, San Diego, California
Poster: The direct NLRP3 inhibitor and Phase 3 anticancer agent, RRx-001, ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice

American Thoracic Society (ATS) Respiratory Innovation Summit

May 2022, San Francisco, California
Oral Presentation: Inflammation and Immunology: Feature Company Showcase
Poster: The ABCs of COVID-19 Related ARDS Treatment
Poster: N-VAX, a universal coronavirus vaccine
Poster: RRx-001, an NLRP3 inflammasome inhibitor, ameliorates bleomycin-induced pulmonary fibrosis

EMBO Workshop “The inflammasomes: The next frontier” 2021

September 2021, Martinsried, Germany
Abstract: The direct NLRP3 inhibitor and Phase 3 anticancer agent, RRx-001, ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice

American Society for Radiation Oncology (ASTRO) 2020

October 2020, Virtual
Oral Presentation: Results of a Randomized, Open Label, Multicenter Trial Assessing the Safety, Dose and Schedule of RRx-001 (R001) in Reducing Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiation (CRT) for Oral Cavity/oropharynx Squamous Cell Carcinoma (OSCC)

American Society of Clinical Oncology (ASCO) Annual Meeting 2020

June 2020, Virtual
Poster: Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule of RRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced.

Abstract: Phase 2 Expansion Cohort in Colorectal Cancer to Evaluate the Safety and Tolerability of RRx-001 Blood Mix.

Abstract: Phase 1 Pilot Study of RRx-001 + Nivolumab in Patients with Traditionally Non-Checkpoint Inhibitor-Responsive Cancers (PRIMETIME).

Abstract: DCE-MRI Evaluation of Ten Patients with Brain Metastases Treated with RRx-001, a CD47 and PD-L1 Downregulator, in a Phase 1/2 Trial Called BRAINSTORM.

Abstract: A phase 3 trial-in-progress called REPLATINUM that compares RRx-001 + a platinum doublet to a platinum doublet in third-line or beyond small cell lung cancer.
Abstract: Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial.
Abstract: Phase 1 Study (PAYLOAD) of RRx-001 + Irinotecan in Patients with Advanced Solid Malignancies.

Society for Neuro-Oncology (SNO) 2018

November 2018, New Orleans, Louisiana
Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases

American Society for Radiation Oncology (ASTRO) 2018

October 2018, San Antonio, Texas
Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases

American Association for Cancer Research (AACR) Annual Meeting 2017

April 2017, Washington, DC.
Abstract: The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry

Abstract: Epigenetic and biological effects of 5-azacytidine and RRX-001 on DLD-1 colorectal cancer cell lines

Abstract: Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF-β pathway activation and markers for fibrosis

American Association for Cancer Research (AACR) Annual Meeting 2016

April 2016, New Orleans, Louisiana
Abstract: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001

Abstract: RRx-001 is effective in temozolomide-sensitive and resistant GBM

Abstract: Improved statistical approaches that account for pseudoprogression in preclinical studies of RRx-001 with immunotherapies

American Society of Hematology (ASH) 2015

December 2015, Orlando, Florida
Oral Presentation: The hypoxia-selective epigenetic agent, RRx-001, triggers apoptosis and overcomes drug-resistance in multiple myeloma cells

Stem Cells Regenerative Medicine Congress 2015

September 2015, Washington, D.C.
Invited Presentation: Restoring efficacy of immunotherapy treatments in oncology with radical oxygen and nitrogen based epigenetic drugs

AACR, Chromatin and Epigenetics in Cancer 2015

September 2015, Atlanta, Georgia
Abstract: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing Phase 2 colorectal cancer study, “ROCKET”

AACR Translation of the Cancer Genome Conference 2015

February 2015, San Francisco, California
Abstract: RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study

American Association for Cancer Research (AACR) Annual Meeting 2014

Apr 2014, San Diego, California
Abstract: Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice

Abstract: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase

Abstract: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models

Meaghan Stirn
Controller & VP of Special Projects


Jeannie Williams
Director of Clinical Operations


Erica Burbano
Clinical Quality Assurance


Angelique Coyle
Associate Regulatory Affairs Specialist


Allison Pratt
Human Resources


Farah Hedjran
Director of Viral Research and Development


Elena Prokopenko
Head of Quality


Garett Soapes
Staff Research Assistant


Cheryl Nickerson


Nacer Abrouk


Associate Professor of Radiation Oncology, Emerita, Stanford University

Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

Chair of the Department of Radiation Oncology, University of Michigan

Isadore Lampe Professor of Radiation Oncology

Kraft Family Professor of Medicine, Medicine, Harvard Medical School

Physician, Oncology, Brigham And Women’s Hospital